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Abstract: Essential oil of Origanum species is well known for antimicrobial activity, but only a few
have been evaluated in narrow spectrum antiprotozoal assays. Herein, we assessed the antiprotozoal
potential of Turkish Origanum onites L. oil and its major constituents against a panel of parasitic
protozoa. The essential oil was obtained by hydrodistillation from the dried herbal parts of O. onites
and analyzed by Gas Chromatography-Flame Ionization Detector (GC-FID) and Gas Chromatography
coupled with Mass Spectrometry (GC-MS). The in vitro activity of the oil and its major components
were evaluated against Trypanosoma brucei rhodesiense, T. cruzi, Leishmania donovani, and Plasmodium
falciparum. The main component of the oil was identified as carvacrol (70.6%), followed by linalool
(9.7%), p-cymene (7%), γ-terpinene (2.1%), and thymol (1.8%). The oil showed significant in vitro
activity against T. b. rhodesiense (IC50 180 ng/mL), and moderate antileishmanial and antiplasmodial
effects, without toxicity to mammalian cells. Carvacrol, thymol, and 10 additional abundant oil
constituents were tested against the same panel; carvacrol and thymol retained the oil’s in vitro
antiparasitic potency. In the T. b. brucei mouse model, thymol, but not carvacrol, extended the
mean survival of animals. This study indicates the potential of the essential oil of O. onites and its
constituents in the treatment of protozoal infections.
Keywords: Origanum onites; Lamiaceae; Turkish oregano; essential oil; carvacrol; thymol;
antiprotozoal; Trypanosoma
1. Introduction
The genus Origanum (Lamiaceae) is represented by 31 taxa including 27 species within the flora of
Turkey [1]. Since ancient times, oregano has been used for flavoring fish, meat, vegetables, and wine,
but also to treat various ailments in traditional Anatolian folk medicine. The first written records on the
utilization of Origanum species in Anatolia date back to Hittite Empire times (1600–1200 BC) [2]. Leaves
and inflorescences of various Origanum species (called “kekik” in Turkish) are still widely used as
a condiment, herbal tea, for production of essential oil, and an aromatic water or hydrosol [3,4]. Orally,
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oregano oil preparations are used as a natural antispasmodic, analgesic, antimicrobial, expectorant, and
carminative agent, and against coughs, digestive disorders, and menstrual problems. The oil is applied,
topically, for its antiseptic and astringent effects, and widely consumed as an oral antiseptic and for
gargling [4]. Oregano herb also serves as an important product for Turkish trade. Due to high quality
product standards, Turkey has recently become a major and preferred supplier of Origanum herb
and its oil to the world markets. The high demand for oregano and its essential oil has also fostered
horticulture of Origanum sp. in the country, reducing wild harvest of the plant [5]. Origanum onites
(Turkish oregano, Izmir oregano, Island oregano, or Cretan oregano) accounts for 80% of all the oregano
exports of Turkey [6]. The plant is characterized by a relatively high yield of essential oil with high
amounts (up to 80%) of carvacrol [4]. Similarly to other Origanum spp., the infusions and the essential
oil of the aerial parts of O. onites are popular in treatment of gastrointestinal disorders, diabetes, high
cholesterol, leukemia, bronchitis, and many other disorders in Turkish traditional medicine [5,7].
Vector-borne parasitic infectious diseases continue to threaten millions of people, particularly
those living in third world countries. Malaria, caused by the protozoan parasite genus Plasmodium, is
transmitted through female Anopheles mosquitoes. The intensive efforts of the WHO and non-profit
organizations and increased public awareness in recent years halved the number of deaths due to malaria
to 435,000 in 2017 [8]. However, other vector-borne diseases, such as trypanosomiasis or leishmaniasis,
still remain neglected tropical diseases. Trypanosoma brucei rhodesiense is the etiological agent of human
African trypanosomiasis (sleeping sickness, HAT) in eastern and southern Africa. The protist parasite
enters the body through the bites of Glossina insects. Approximately 65 million people are at risk of
HAT [9]. Trypanosoma cruzi causes Chagas’ disease (American trypanasomiasis), which is transmitted
by blood-sucking triatomine bugs. About 7 million people, mostly in Latin America, are infected [10].
Leishmaniasis has three main forms—visceral, cutaneous, and mucocutaneous leishmaniasis—caused
by different Leishmania parasites. Several Leishmania species (L. donovani, L. infantum, and L. chagasi) are
the causative agents of visceral leishmaniasis (Kala-azar), which represents the most dangerous form
of the disease. The parasite is transmitted to human by infected female phlebotomine sandflies. It
is estimated that 50,000–90,000 new cases occur worldwide each year [11]. If left untreated, all these
protozoal diseases are fatal. Although sustained efforts have reduced the numbers of cases and the
death toll, the occurrence of drug-resistant strains and the adverse effects of the currently used drugs
require new, safe, and effective antiprotozoal agents.
As exemplified by Cinchona bark and Artemisia annua herba, as well as their active principles
quinine and artemisinin, medicinal plants and their secondary metabolites represent highly valuable
sources for new compounds against parasitic diseases. The majority of research efforts into the effects
of plants on parasitic infections have used aqueous or alcoholic extracts, although essential oils are
also efficacious in treating or preventing protozoal diseases [12]. Several Origanum spp. have been
shown to inhibit the growth of internal and external parasites and protozoan infections in previous
studies [13–16]. Turkish Origanum onites has also been extensively studied for numerous in vitro
and in vivo biological activities [7,17]; however, no detailed study exists on its antiprotozoal activity.
The aim of this present study was therefore to comprehensively evaluate the in vitro and in vivo
antiprotozoal activity of Turkish O. onites essential oil and its 12 abundant components.
2. Results
2.1. Chemical Composition of the Essential Oil
Hydrodistillation of the aerial parts ofO. onites delivered a relatively high yield of essential oil (2.0%
v/w). Overall, 71 compounds, representing 99.9% of the total volatiles, were characterized by GC-FID
and GC-MS analysis (Table 1). Chemically, the essential oil was predominated by carvacrol (70.6%,
Figure 1). The other major constituents of the oil were linalool (9.7%), p-cymene (7.0%), γ-terpinene
(2.1%), and thymol (1.8%). Reasonable levels of myrcene and α-terpinene (each 1%), terpinen-4-ol,
β-caryophyllene, and α-terpineol (all 0.7%), as well as α-pinene and borneol (both 0.5%), were also
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detected. Oxygenated monoterpenes comprised the largest portion of the oil composition (84.9%), but
monoterpene hydrocarbons (12.9%), sesquiterpene hydrocarbons (1.1%), and other components (13%)
e.g., alcohols, esters, and aldehydes were also determined in the oil.
Table 1. The chemical composition of Origanum onites L. essential oil.
No RRI a Compound % Identification Method b
1 1018 Methyl 2-methyl-butyrate 0.1 MS
2 1024 Methyl 3-methyl-butyrate trc MS
3 1032 α-Pinene 0.5 RRI, MS
4 1035 α-Thujene 0.1 RRI, MS
5 1076 Camphene 0.2 RRI, MS
6 1118 β-Pinene tr RRI, MS
7 1159 δ-3-Carene 0.1 MS
8 1174 Myrcene 1.0 RRI, MS
9 1188 α-Terpinene 1.0 RRI, MS
10 1203 Limonene 0.2 RRI, MS
11 1213 1,8-Cineole 0.3 RRI, MS
12 1218 β-Phellandrene 0.2 RRI, MS
13 1246 (Z)- β-Ocimene 0.1 MS
14 1255 γ-Terpinene 2.1 RRI, MS
15 1280 p-Cymene 7.0 RRI, MS
16 1290 Terpinolene 0.1 RRI, MS
17 1393 3-Octanol 0.1 MS
18 1450 trans-Linalool oxide (Furanoid) tr MS
19 1452 α,p-Dimethylstyrene tr MS
20 1452 1-Octen-3-ol 0.3 MS
21 1474 trans-Sabinene hydrate 0.4 MS
22 1478 cis-Linalool oxide (Furanoid) 0.1 MS
23 1497 α-Copaene tr MS
24 1532 Camphor tr RRI, MS
25 1553 Linalool 9.7 RRI, MS
26 1571 trans-p-Menth-2-en-1-ol tr MS
27 1610 Calarene (=β-gurjunene) tr MS
28 1611 Terpinen-4-ol 0.7 RRI, MS
29 1612 β-Caryophyllene 0.7 RRI, MS
30 1620 Selina-5,11-diene tr MS
31 1628 Aromadendrene 0.2 MS
32 1638 cis-p-Menth-2-en-1-ol tr MS
33 1645 cis-Isodihydrocarvone tr MS
34 1661 Alloaromadendrene tr MS
35 1670 trans-Pinocarveol tr RRI, MS
36 1682 δ-Terpineol tr MS
37 1687 α-Humulene tr RRI, MS
38 1689 trans-Piperitol (=trans-p-Menth-1-en-3-ol) tr MS
39 1704 γ-Muurolene tr MS
40 1706 α-Terpineol 0.7 RRI, MS
41 1708 Ledene 0.1 MS
42 1719 Borneol 0.5 RRI, MS
43 1740 α-Muurolene tr MS
44 1751 Carvone 0.1 RRI, MS
45 1773 δ-Cadinene 0.1 MS
46 1776 γ-Cadinene tr MS
47 1798 Methyl salicylate tr RRI, MS
48 1845 trans-Carveol 0.1 MS
49 1864 p-Cymen-8-ol 0.1 RRI, MS
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Table 1. Cont.
No RRI a Compound % Identification Method b
50 1940 4-Isopropyl salicylaldehyde 0.1 MS
51 1983 Piperitenone oxide tr RRI, MS
52 2008 Caryophyllene oxide 0.3 RRI, MS
53 2030 Methyl eugenol tr RRI, MS
54 2033 Epiglobulol tr MS
55 2050 (E)-Nerolidol tr MS
56 2071 Humulene epoxide-II tr MS
57 2098 Globulol tr MS
58 2104 Viridiflorol tr MS
59 2113 Cumin alcohol tr RRI, MS
60 2144 Spathulenol 0.1 MS
61 2181 Isothymol (=2-Isopropyl-4-methyl phenol) tr MS
62 2185 γ-Eudesmol tr MS
63 2186 Eugenol tr RRI, MS
64 2198 Thymol 1.8 RRI, MS
65 2221 Isocarvacrol (=4-Isopropyl-2-methyl phenol) tr MS
66 2239 Carvacrol 70.6 RRI, MS
67 2246 3-Isopropyl-2-methyl phenol 0.1 MS
68 2250 α-Eudesmol tr MS
69 2257 β-Eudesmol tr MS
70 2300 3-Isopropyl-5-methyl phenol tr MS
71 2392 Caryophylla-2(12),6-dien-5β-ol(=Caryophyllenol II) tr MS
Monoterpene hydrocarbons 12.9
Oxygenated monoterpenes 84.9
Sesquiterpene hydrocarbons 1.1
Oxygenated sesquiterpenes 0.4
Diterpenes 0.6
Others 12.9
Total 99.9
a RRI: Relative retention indices calculated against n-alkanes; % calculated from FID data b Identification method
based on the relative retention indices (RRI) of genuine standard compounds on the HP Innowax column; MS,
identification was performed on the basis of computer matching of the mass spectra with those of the Wiley and
MassFinder libraries and comparison with literature data. c tr, < 0.01.
2.2. In Vitro Antiprotozoal Activity and Cytotoxicity of the Essential Oil
The essential oil was tested in vitro for activity against blood-stage forms of multidrug-resistant
Plasmodium falciparum, trypomastigote forms (mammalian stage) of Trypanosoma brucei rhodesiense
and T. cruzi, and towards amastigotes (the clinically relevant form) of Leishmania donovani parasites.
As shown in Table 2, the oil showed significant in vitro activity against African trypanosome T. b.
rhodesiense (IC50 0.18 µg/mL) and moderate antileishmanial (IC50 17.8 µg/mL) and antiplasmodial (IC50
7.9 µg/mL) effects. No inhibitory activity was observed against the American trypanosome T. cruzi at
the highest concentration tested (90 µg/mL). The oil was devoid of any toxicity against the mammalian
cell line (L6) even at the highest test concentration (>90 µg/mL).
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Table 2. In vitro antiprotozoal activity and the cytotoxic potential of the O. onites essential oil and its
components (IC50 values in µg/mL). Reference (standard) compounds: a melarsoprol, b benznidazole,
c miltefosine, d chloroquine, e phodophyllotoxin.
Sample Trypanosoma brucei Trypanosoma Leishmania Plasmodium Cytotoxicity
rhodesiense cruzi donovani falciparum L6 cells
Standard compd 0.003 a 0.44 b 0.2 c 0.056 d 0.004 e
O. onites Essential Oil 0.18 ± 0.004 >90 17.8 ± 3.7 7.9 ± 0.3 >90
Carvacrol 0.15 ± 0.04 >90 13.1 ± 3.9 6.4 ± 0.9 48.8 ± 1.1
Thymol 0.11 ± 0.01 >90 17.3 ± 4.1 5.7 ± 0.03 51.8 ± 6.2
α-Pinene 0.42 ± 0.24 >90 81.9 ± 9 10.7 ± 1.2 87.8 ± 3
Myrcene 22 ± 14.8 >90 48.2 ± 12.7 >20 >90
α-Terpinene 3.1 ± 1.6 49.1 ± 7.3 10.5 ± 1.7 3.7 ± 1.5 84.7 ± 4.3
γ-Terpinene 32.9 ± 26 >90 >90 >20 >90
p-Cymene 45.0 ± 27 >90 >90 >20 >90
L-Linalool 3.6 ± 2.5 >90 86.3 ± 2.8 >20 >90
Terpinen-4-ol 0.66 ± 0.4 46.8 ± 7.4 68.7 ± 14.2 >20 43.3 ± 16.5
β-Caryophyllene 28.9 ± 11.8 50.1 ± 12.5 52.4 ± 17.4 12.8 62.2 ± 7
α-Terpineol 0.56 ± 0.4 61.0 ± 2.1 75.9 ± 4.7 >20 32.3 ± 0.1
Borneol 24.3 ± 11.8 >90 52.1 ± 16.6 >20 >90
Carvacrol Methyl
Ether 17.0 ± 22 >90 17.5 ± 1.7 >20 >90
Thymol Methyl Ether 4.1 ± 1.97 >90 86.0 ± 1.9 >20 >90
Thymoquinone 0.11 ± 0.02 18.2 ± 4.3 1.7 ± 0.16 2.6 ± 0.16 20.5 ± 8.1
The stock solutions were prepared by dissolving the essential oil and its components in 100% Dimethylsulfoxide
at 10 mg/mL concentration and further diluted in assay medium (maximum DMSO concentration 1%). The IC50
values are means of two independent determinations ± deviation from the mean.
2.3. In Vitro Activity and Cytotoxicity of the Individual Constituents of the Essential Oil
The significant in vitro antiprotozoal activity of the essential oil encouraged us to test carvacrol,
the main phenolic monoterpenoid constituent of the oil, as well as its position isomer, thymol (Figure 1).
Interestingly, both compounds exhibited almost identical antitrypanosomal activities against
T. b. rhodesiense, with IC50 values of 110 ng/mL (thymol) and 150 ng/mL (carvacrol) (Table 2). Their
leishmanicidal and plasmocidal potentials were also highly comparable to that of the oil, and both
compounds were inactive against T. cruzi (Table 2). Pure carvacrol and thymol showed some low
toxicity against mammalian cells; however, their selectivity indices (IC50 value against L6 mammalian
cells/IC50 value against parasite), for example against T. b. rhodesiense, were very high (454.4 for thymol
and 327.5 for carvacrol, Table 2).
The significant antiprotozoal activity of carvacrol and thymol prompted us to test their derivatives,
carvacrol methyl ether and thymol methyl ether (Figure 1). The latter compound (thymol ME) showed
moderate antitrypanosomal activity against African trypanosomes (IC50 4.1 µg/mL), and this was four
times stronger than that observed for CME (IC50 17.0µg/mL). However, both activities were significantly
lower than the parent compounds (Table 2). We further tested thymoquinone (Figure 1), the quinone
derivative of thymol. This compound was equipotent towards T. b. rhodesiense, with identical
IC50 values to thymol (IC50 110 ng/mL), and showed approximately 3- to 10-fold higher activities
against L. donovani (IC50 1.7 µg/mL) and P. falciparum (IC50 2.6 µg/mL). However, during the first
round of antiprotozoal testing, we observed instability of the thymoquinone sample, which exhibited
a color change. When the testing was repeated (four times) against the most susceptible parasite,
T. b. rhodesiense, the observed IC50 values increased severely from 0.123 µg/mL to 039 µg/mL, 8.61 µg/mL,
and finally to 42.1 µg/mL. In initial testing, thymoquinone exerted 2.5-fold higher cytotoxicity on L6
cells (IC50 20.5 µg/mL) than thymol (Table 2), indicating a lower selectivity towards parasites.
Carvacrol is the main component of the essential oil (70.6%), whereas thymol, which exists
therein with much lower abundance (1.8%), exhibited in vitro antiparasitic activity equal to carvacrol.
This prompted us to test other major constituents of the oil, i.e., L-linalool (9.7%), p-cymene (7.0%),
andγ-terpinene (2.1%), plus several other components of the oil. For the latter, with comparatively lower
percentages in the oil, we set a threshold (0.5%) to evaluate their potential. Thus, in addition to carvacrol
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and thymol, 10 additional constituents of the oil were also submitted to the same in vitro bioactivity
assessments. As displayed in Table 2, only α-pinene, α-terpineol, and terpinen-4-ol showed remarkable
trypanocidal activity towards T. b. rhodesiense (IC50 values 0.42, 0.56, and 0.66 µg/mL, respectively) and
displayed low or moderate toxicity to L6 cells (IC50 values 87.8, 32.3, and 43.3 µg/mL, respectively). In
addition, α-terpinene showed equipotent trypanocidal (T. b. rhodesiense) and antimalarial potential
(IC50 values 3.1 and 3.7 µg/mL, respectively). L-Linalool was the last compound with reasonable
antitrypanosomal activity against T. b. rhodesiense (IC50 3.6 µg/mL). All other compounds showed low
to no in vitro antiprotozoal activity against the set of protozoan parasites in the test panel (Table 2).
2.4. In Vivo Trypanocidal Activity of Carvacrol and Thymol
Based on their potent trypanocidal activities, the essential oil of O. onites and its main constituent
carvacrol were selected for an in vivo activity study against T. brucei brucei STIB795 mouse model. We
also decided to test thymol, which exhibited equal in vitro activity to carvacrol, on the same animal
model for comparison. The oil and its components were applied intraperitoneal (i.p) at a 100 mg/kg
dose, but failed to show any significant in vivo activity. Notably, the mice treated with thymol showed
a mean survival of 9 days, which represented an extension of survival compared to 5.25 days for the
untreated control group (Table 3). The mice treated with the positive control (pentamidine) were cured
and survived over 30 days. Due to the limited in vivo efficacy of the tested compounds, other less
active compounds, namely α-pinene, α-terpineol, and terpinen-4-ol, were not submitted to an in vivo
study. Thymoquinone, which was equally active against T. b. rhodesiense in vitro to carvacrol and
thymol, was also excluded from animal studies based on its relatively higher in vitro toxicity and
instability observed during the in vitro testing.
Table 3. In vivo activity of O. onites oil and its components against T. brucei brucei STIB795 mouse model.
Compound Dosing Regimen(mg/kg) × 4 days Injection Cured/Infected
Mean Survival
(days)
Essential oil 100 i.p. 0/4 5.25
Thymol 100 i.p. 0/4 9.0
Carvacrol 100 i.p. 0/4 5.25
Control a - - 0/4 5.25
Standard b 5.0 i.p. 4/4 >30
a Untreated control to determine the mean survival. b Pentamidine.
3. Discussion
Similarly to many Lamiaceae plants, Origanum species accumulate high levels of essential oil
with varying yield and chemical composition, depending on location or origin. O. onites is a narrowly
distributed East Mediterranean species growing mainly in Turkey and Greece, which comprises one
of the major herbs of the oregano trade worldwide [18]. In a previous study, the essential oil of
Greek O. onites collected from Chios, a Greek island bordering with the Turkish mainland, gave the
highest essential oil yield (3%–7% v/m dry leaves and inflorescences) and the highest carvacrol content
(69.0%–92.6%) ([18]. Turkish O. onites has two chemotypes: (i) carvacrol-type (with 66.5%–80.4%
carvacrol content) and (ii) linalool-type (with 90.0%–91.9%) linalool content) [6]. Obviously, the plant
material studied herein represents a carvacrol chemotype. The oil yield and the chemical composition
of the Turkish O. onites essential oil also show seasonal variations. The maximum essential oil and
highest carvacrol content in the leaves has been demonstrated to occur in July [19].
In Turkey, O. onites herb and its essential oil and hydrosol are routinely used for a number
of ailments, and have been tested for various biological and pharmacological activities [7]. In the
continuation of our efforts to identify antiprotozoal plants and natural products from Turkish Lamiaceae
plants [20–22], we decided to study the in vitro antiprotozoal activity of Turkish O. onites essential oil
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against a panel of protozoan parasites, and tested its potential toxicity towards a mammalian cell line
to determine the selectivity. The oil was moderately active against P. falciparum and L. donovani, but
exhibited very high efficacy against trypanomastigote forms of African trypanosome T. b. rhodesiense,
while being inactive versus the same forms of American trypanosome T. cruzi. Furthermore, the oil
showed no toxicity towards mammalian cells. Thus, we decided to assess the in vitro activity of
carvacrol, the principle compound of the O. onites oil, its isomer thymol, and 10 other individual
terpenoid components (with up to 0.5% abundance in the oil) for their potential contribution to the
overall activity of the oil. Carvacrol and thymol exerted activity equal to that of the oil against all
test organisms, with a very high selectivity to T. b. rhodesiense. When tested for in vivo trypanocidal
activity in mice, only thymol extended the survival time of infected mice, whereas the essential oil and
carvacrol were inactive. To our knowledge, this is the first report of any in vivo activity of thymol in
a T. brucei in vivo animal model.
The antimicrobial activity of essential oils and their components has long been recognized, and has
continued to receive research interest in recent years. In comparison to numerous antibacterial or
antifungal activity screening studies, little work has been done to assess the potential of volatile oils
and their individual constituents for treatment of endo- or ectoparasites [12,23]. Essential oils of
a few Origanum species have been reported to exhibit antiparasitic activities against human or animal
parasites. In human trials, orally given emulsified oregano oil has shown high activity against intestinal
parasites Blastocystis hominis, Entamoeba hartmanni, and Endolimax nana [14]. A powder containing 5%
Greek O. vulgare subsp. hirtum oil (and 95% natural feed-grade inert carrier) was also effective against
chickens infected with Eimeria tenella, an endoparasite that causes hemorrhagic cecal coccidiosis in
poultry [15]. A highly diluted (1%) aqueous solution of oregano oil kills head lice, Pediculus humas
capitis, an ectoparasite [13].
The essential oils of several Origanum species have been submitted to narrow-spectrum
antiprotozoal activity studies, generally on single parasites or different species of the same parasite
genus. Fujisaki and coworkers (2012) evaluated the antiplasmodial activity of 47 essential oils,
including oregano oil (species name of the plant and full chemical composition of the oil were not
given) containing 26% carvacrol. The oil, as well as its constituents thymol and carvacrol, showed
in vitro antimalarial activity against P. falciparium FCR-3 strain with an IC50 value of 10 µg/mL [24].
In vitro antimalarial potency of the essential oil of O. vulgare [25] and O. compactum collected from
Morocco [26] ranged from very low to moderate, respectively. Carvacrol was reported to be inactive
against chloroquine-resistant P. falciparum strain (IC50 > 1 mM) [27], whereas thymol exhibited in vitro
antimalarial activity with IC50 value of 4.5 µg/mL [28]. The latter activity is very similar to that
observed in our study.
Brazilian O. virens essential oil showed little activity against L. infantum promastigotes (IC50
196 µg/mL, MTT assay 24 h) [29], and even poorer activity was exerted by Brazilian O. vulgare
towards L. amazonesis promastigotes (IC50 405.5 µg/mL, MTT, 72 h), with the major components
cis-p-menth-2-en-1-ol (33.9%) and linalyl acetate (13.9%) [30]. When the essential oil from the flowering
stage aerial parts of Moroccan O. compactum was tested against L. tropica, L. major, and L. infantum,
the highest potency was observed against the latter (IC50 0.02 µg/mL, MTT, 72 h incubation). This oil
contains comparable amounts of carvacrol, thymol, p-cymene, and γ-terpinene [31]). Moderate in vitro
activity of carvacrol against various Leishmania spp., for example against L. infantum (IC50 value of
7.35 µg/mL), has been demonstrated [32]. Monoterpene phenols thymol and carvacrol show activity
against promastigote forms of L. chagasi [33,34] with IC50 values of 9.8 µg/mL (thymol) and 2.3 µg/mL
(carvacrol). Semi-synthetically prepared Morita–Baylis–Hillman adducts of thymol and carvacrol
exert superior activity and lower toxicity in vitro than their parent compounds against promastigotes
of L. amazonensis, one of the causative agents of cutaneous leishmaniasis [35]. Thymol, as well as
its benzoyl and acetyl derivatives, exhibit in vitro leishmanicidal activity against both promastigotes
and amastigotes of L. infantum chagasi [36]. A very recent study by Youssefi et al. (2019) reported the
moderate and comparable leishmanicidal effects of both carvacrol and thymol against L. infantum
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promastigotes (IC50 values 9.8 and 7.2 µg/mL, respectively) upon a 24 h MTT assay [37]. Several
Origanum spp. essential oils, as well as thymol and carvacrol, have been evaluated against several
Leishmania species before, but the current study reported for the first time the effect of oregano oil and its
constituents on amastigotes (the clinically relevant form) of L. donovani causing visceral leishmaniasis,
the most serious form of the disease.
Santoro et al. (2007) investigated the effect of essential oil of O. vulgare on the growth and
ultrastructure of evolutionary forms of American trypanosome T. cruzi [38]. The IC50 values obtained
by 24 h incubation of epimastigotes and trypomastigotes with oregano oil were low (175 and 115 µg/mL,
respectively). Thymol, tested at the same test conditions, showed a better efficacy, with IC50 values of
62µg/mL (epimastigotes) and 53µg/mL (trypomastigotes) [38]. In another study by Escobar et al. (2010),
thymol (IC50 3.2 µg/mL) was found to be active against intracellular amastigotes of T.-cruzi-infected
Vero cells, with a selective index greater than 10 [39].
Human African trypanosomiasis is caused by two subspecies of T. brucei brucei, namely T. brucei
gambiense and T. brucei rhodesiense. The essential oil of Portuguese O. virens, with a somewhat similar
chemical composition (carvacrol 68.2%, γ-terpinene 7.9%, p-cymene 7.4%, β-myrcene 2.4%, and thymol
2.1%) to Turkish O. onites showed moderate in vitro trypanocidal activity against T. b. brucei (IC50
24.0 µg/mL) [40]. These results are 130 times lower than what we obtained with O. onites oil against
T. brucei rhodesiense. The discrepancy may stem from the use of different Trypanosoma species (AnTart 1
strain, wild type), incubation time, and different methodologies. Carvacrol and thymol demonstrated
activity against T. brucei brucei (life stage or form has not been reported) with IC50 values of 11.3 and
22.9 µg/mL [41]. To our knowledge, thymol has never been tested or reported to have in vitro activity
against T. brucei rhodesiense subspecies.
Several studies have assessed the in vivo activity of thymol and its semi-synthetic derivatives
against Leishmania- and Trypanosoma-type parasitic kinetoplastids. The administration of benzoyl and
acetyl–thymol to BALB/c mice infected with L. infantum chagasi at 100 mg/kg/day (i.p.) dose for 30 days
demonstrated in vivo activity [36]. Despite the low leishmanicidal activity, the oral administration of
thymol (and its di-nitro derivative) in mice for 30 days reduced the parasite burden significantly (67.8%
versus the standard glucantime 100%) [42]. Thymol was also shown to exhibit anti-Trypanosoma-cruzi
effect in vivo. Upon application of thymol to infected albino mice at 200 mg/kg/day dose by intragastric
route, a significant reduction in parasitemia on the 22nd day post-infection was observed [43].
Youssefi et al. (2019) tested carvacrol, thymol, and linalool (100 mg/kg, i.p. route) in hamsters infected
with L. infantum, and concluded thymol to be the most effective and the safest metabolite with lowest
side effects on the hamster liver [37]. To our knowledge, ours was the first in vivo study showing the
potential of thymol to extend the life span of mice infected with African trypanosomes in a T. brucei
brucei model.
Among the other three major constituents of the Turkish O. onites essential oil (linalool, p-cymene,
and γ-terpinene), only L-linalool, which is the main linalool enantiomer found in Origanum essential
oils [44], showed reasonable T. b. rhodesiense activity (IC50 3.6 µg/mL). p-Cymene and γ-terpinene were
devoid of any significant activity against any of the parasites tested. When the other seven constituents
with up to 0.5% concentrations in the oil were evaluated against the protozoan panel, T. b. rhodesiense
emerged as the most susceptible parasite. In particular, α-pinene, terpinen-4-ol, and α-terpineol were
most active, however they lacked significant activity to other three parasites in the test panel (Table 2).
Mikus et al. (2000) have shown good activity of terpinen-4-ol towards T. brucei bloodstream forms
(ED50 0.02 µg/mL) with 1000-fold more selectivity to the parasite than to the human cell line [45].
α-Pinene has been shown to be active against T. cruzi epimastigotes and amastigotes (IC50 values
2.74 and 1.92 µg/mL, respectively [46], as well as blood stream trypomastigotes cultures of T. brucei
brucei with an IC50 value of 2.9 µg/mL [40]. To our knowledge, this study was the first report of
α-terpineol. α-Terpinene was equipotent against both T. b. rhodesiense and P. falciparum with negligible
toxicity. Treatment of T. evansi-infected mice with α-terpinene has been shown to extend animal
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longevity [47]. The current study reported for the first time in vitro antiplasmodial, antileishmanial.
and the trypanocidal activity against T. b. rhodesiense and T. cruzi of α-terpinene.
The mechanism underlying the antimicrobial, including antiprotozoal, actions of essential oils
and their monoterpenes is not fully understood [34]. Due to their highly lipophilic nature, which
permits easy absorption by the cell membrane, it was generally accepted that they were involved in the
alteration and disruption of lipophilic membranes and inhibition of parasites’ lipid metabolism [48,49].
However, a flow cytometry study performed by Santoro et al. (2007) indicated that the essential oils
permeate the cell membrane and kill the parasites by affecting cytoplasmic metabolic pathways or
organelles, and not by compromising the parasite membrane integrity [38]. Therefore, it seems the
mechanism of action for oils and their constituents is rather complex. Several new studies investigated
the potential targets using in silico methods [50,51].
The current study showed that carvacrol and thymol fully retain the in vitro antiprotozoal activity of
the O. onites essential oil, without showing significantly superior activity to the oil. Such a phenomenon,
i.e., that the single main components of essential oils do not exceed the activity of the original oil, has
been observed previously [52]. Some studies have shown a synergistic antiparasitic activity, in vitro
and in vivo, of a combination of several single oil components [52,53]. It is also noteworthy that thymol
and carvacrol were equipotent in vitro against T. b. rhodesiense. When tested in vivo in mice, thymol
had some effect, but carvacrol and the essential oil were inactive. Discrepancy between in vitro and
in vivo efficacy is a complex and common issue in drug discovery stemming from, for example, low
solubility, in vivo instability, hydrolysis, and oxidation of the compound of interest. Essential oils are
oily mixtures of lipophilic, liquid, and volatile compounds. Diminished in vivo effects of essential
oils in animals have been reported [54,55]. Such non-optimal pharmacokinetic and physiochemical
properties, for example, very rapid absorption, poor solubility, poor bioavailability, and elimination
rate, are considered as major hurdles in the development of essential oils and their volatile components
as drugs [56,57]. Solid formulation techniques (e.g., microencapsulation, liposomes, nanoparticles)
are used for their controlled release and targeted delivery of such hydrophobic oils [57–60]. Such
techniques also address additional issues related to essential oils and their terpenoid constituents
(strong odor, taste, evaporation, degradation, and sensitivity to light, air, and temperature) [61].
The importance of the presence of the hydroxyl group in the bioactivity of phenolic compounds
such as carvacrol and thymol is well known [62,63]. Accordingly, the methyl ether derivatives of
these compounds were 40–90 times less potent towards T. b. rhodesiense than the original compounds
(Table 2). The activity of thymol is attributed to the characteristic feature of the phenolic hydroxyl
group, which may be more acidic than carvacrol, and hence more active, due to the presence of
a system of delocalized electrons [63]. Thymoquinone has equipotent trypanocidal activity to thymol,
and exerts enhanced antileishmanial and antiplasmodial effects; however, due to observed instability
during in vitro assays, it was excluded from the animal model studies. To our knowledge, this is
most comprehensive and in-depth study performed on the essential oil of any Origanum species that
included in vitro antiprotozoal activity assessments of the oil and its 12 constituents against four
different parasitic protozoa, cytotoxicity, and finally in vivo activity testing.
4. Materials and Methods
4.1. Reagents and Chemicals
Pure essential oil compounds in high purity (>95%), reagents, and solvents were obtained from
various commercial sources, i.e., Sigma-Aldrich, Fluka, Merck, Frutarom, and Roth. The origin of
the standard compounds used in bioassays are as follows: chloroquine diphosphate (Sigma-Aldrich,
Buchs, Switzerland), benznidazole (Epichem Ltd., received from DNDi, Geneva), melarsoprol (Arsobal
Sanofi-Aventis, received from WHO, Geneva), miltefosine (Sigma-Aldrich, Buchs, Switzerland),
podophyllotoxin (Sigma-Aldrich, Buchs, Switzerland), and pentamidine (Sigma-Aldrich, Buchs,
Switzerland).
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4.2. Plant Material and Isolation of the Essential Oil
The plant material was acquired from Altes Ltd. (Antalya, Turkey) and identified by one of us
(K.H.C. Baser, Turkey). A voucher specimen is deposited at Department of Pharmacognosy, Faculty of
Pharmacy, Anadolu University, Eskisehir (ESSE 14567). The whole air-dried aerial parts of the plant
were subjected to hydrodistillation for 3 h using a Clevenger apparatus to produce the essential oil.
The oil yield was 2% (v/w).
4.3. Gas Chromatography Analyses
The O. onites oil was analyzed by GC-FID and GC-MS using an Agilent GC–mass selective detector
(MSD) system. The GC-MS analyses were carried out with an Agilent 5975 GC-MSD system. An
Innowax fused silica capillary column (60 m × 0.25 mm, 0.25 µm film thickness) was used with helium
as the carrier gas (0.8 mL/min). The oven temperature was kept at 60 ◦C for 10 min, then programmed
to 220 ◦C at a rate of 4 ◦C/min, then maintained constant at 220 ◦C for 10 min, and finally programmed
to 240 ◦C at a rate of 1 ◦C/min. The injector temperature was set at 250 ◦C. The split flow was adjusted
at 50:1. Mass spectra were recorded at 70 eV over the mass range m/z 35–450. The GC analyses
were performed using an Agilent 6890N GC system. The FID detector temperature was set to 300 ◦C,
and the same operational conditions were used with a duplicate of the same column employed in
GC-MS analyses. Simultaneous autoinjection was done to obtain equivalent retention times. Relative
percentages of the separated compounds were calculated from integration of the peak areas in the
GC-FID chromatograms (Table 1). Identifications of the essential oil components were carried out
by comparison of their relative retention times with those of authentic samples or by comparison of
their relative retention indexes (RRI) to series of n-alkanes. Computer matching against commercial
(Wiley GC/MS Library, MassFinder Software 4.0) [64,65] and in-house “Bas¸er Library of Essential Oil
Constituents” was built up by genuine compounds and components of known oils.
4.4. In Vitro Assay for Plasmodium falciparum
Activity against the erythrocytic stages of P. falciparum was determined using an in vitro modified
[3H]-hypoxanthine incorporation assay [66,67], using the chloroquine- and pyrimethamine-resistant K1
strain [68]. Compounds were dissolved in DMSO at 10 mg/mL and further diluted in medium before
added to parasite cultures incubated in RPMI 1640 medium without hypoxanthine, supplemented with
HEPES (5.94 g/l), NaHCO3 (2.1 g/L), neomycin (100 U/mL), AlbumaxR (5 g/L), and washed human
red cells A+ at 2.5% haematocrit (0.3% parasitaemia). Serial drug dilutions of seven 3-fold dilution
steps covering a range from 90 to 0.123 µg/mL were prepared. The 96 well plates were incubated in
a humidified atmosphere at 37 ◦C; 4% CO2, 3% O2, 93% N2. After 48 h 50 µL of 3H-hypoxanthine
(=0.5 µCi) was added to each well of the plate. The plates were incubated for a further 24 h under the
same conditions. The plates were then harvested with a Betaplate™ cell harvester (Wallac, Zurich,
Switzerland), and the red blood cells transferred onto a glass fiber filter then washed with distilled
water. The dried filters were inserted into a plastic foil with 10 mL of scintillation fluid, and counted
in a Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). The results were recorded
as counts per minute (CPM) per well at each drug concentration and expressed as percentage of the
untreated controls. IC50 values were calculated from the sigmoidal inhibition curves using Microsoft
Excel. Chloroquine was used as positive control drug.
4.5. In Vitro Assay for Trypanosoma brucei rhodesiense
Trypanosoma brucei rhodesiense STIB 900 strain, isolated in 1982 from a human patient in Tanzania
and, after several mouse passages, cloned and adapted to axenic culture conditions, was used in this
assay [69]. Minimum essential medium (50 µL) supplemented with 25 mM HEPES, 1 g/L additional
glucose, 1% MEM non-essential amino acids (100×), 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate,
and 15% heat inactivated horse serum was added to each well of a 96 well microtiter plate. Serial
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drug dilutions of seven 3-fold dilution steps covering a range from 90 to 0.123 µg/mL were prepared,
and then 4 × 104 blood stream forms of T. b. rhodesiense STIB 900 in 50 µL were added to each well
and the plate was incubated at 37 ◦C under a 5% CO2 atmosphere for 72 h. Resazurin solution
(resazurin, 12.5 mg in 100 mL double-distilled water) (10 µL) was then added to each well and
incubated for a further 2–4 h [70]. At the end of the assay, the plates were read with a Spectramax
Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an
excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analyzed using
the microplate reader software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA).
Melarsoprol was used as standard drug.
4.6. In Vitro Assay for Trypanosoma cruzi
Rat skeletal myoblasts (L-6 cells) were seeded in 96 well microtiter plates (2000 cells/well) in
100 µL RPMI 1640 medium with 10% FBS and 2 mM L-glutamine for 24 h. After that, the medium was
removed and replaced by 100 µL per well containing 5000 trypomastigote forms of T. cruzi Tulahuen
strain C2C4, containing the β-galactosidase (Lac Z) gene [71]. The medium was removed from the
wells after 48 h, and replaced with 100 µL fresh medium with or without a serial drug dilution of seven
3-fold dilution steps covering a range from 90 to 0.123µg/mL. After 96 h of incubation, the plates were
inspected under an inverted microscope to assure growth of the controls and sterility, after which the
substrate CPRG/Nonidet (50 L) was added to all wells. A color reaction developed within 2–6 h and
could be read photometrically at 540 nm. Data were transferred into the graphic program Softmax Pro
(Molecular Devices Cooperation, Sunnyvale, CA, USA) and the IC50 values were calculated from the
sigmoidal dose response curves. Benznidazole was the reference drug.
4.7. In Vitro Assay for Leishmania donovani
Amastigotes of L. donovani (strain MHOM/ET/67/L82) were grown in axenic culture at 37 ◦C
in SM medium [72] at pH 5.4 supplemented with 10% heat-inactivated FBS under an atmosphere
of 5% CO2. Culture medium (100 µL) with 105 amastigotes from axenic culture with or without
a serial drug dilution was seeded in 96 well microtiter plates. Serial drug was prepared covering
a range of dilutions from 90 to 0.123µg/mL. After 72 h of incubation, the plates were inspected under
an inverted microscope to assure growth of the controls and sterile conditions. Subsequently, 10 µL
resazurin solution (12.5 mg resazurin dissolved in 100 mL double-distilled water) was added to each
well and the plates were incubated for another 2 h. The plates were then read with a Spectramax
Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using
an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analyzed
using the software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). A decrease
of fluorescence (=inhibition) was expressed as percentage of the fluorescence of control cultures and
plotted against the drug concentrations. From the sigmoidal inhibition curves, the IC50 values were
calculated. Miltefosine was used as a reference drug.
4.8. In Vitro Assay for Cytotoxicity on Mammalian Cells
Assays were performed in 96 well microtiter plates (4 × 104 L6 cells/well), each well containing
100 µL of RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% FBS. L6 cells
are a primary cell line derived from rat skeletal myoblasts [73,74]. Serial drug dilutions of seven
3-fold dilution steps covering a range from 90 to 0.123µg/mL were prepared. After 72 h of incubation,
the plates were inspected under an inverted microscope to assure growth of the controls and sterile
conditions. Resazurin solution (10µL) (12.5 mg resazurin in 100 mL double-distilled water) was
then added to each well and the plates incubated for another 2 h. The plates were then read with
a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA)
using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analyzed
using the microplate reader software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA,
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USA). From the sigmoidal inhibition curves, the IC50 values were calculated. Podophyllotoxin was the
positive control.
4.9. In Vivo Trypanocidal Activity Assessment
In vivo efficacy studies in mice were conducted at the Swiss Tropical and Public Health Institute
(Basel) (License number 2813) according to the rules and regulations for the protection of animal rights
(“Tierschutzverordnung”) of the Swiss “Bundesamt für Veterinärwesen”. They were approved by the
veterinary office of Canton Basel-Stadt, Switzerland. Groups of four female NMRI mice weighing 20 to
25 g were infected i.p. on Day 0 (d0) with 105 bloodstream forms of T. brucei brucei STIB 795, which is
a derivative of strain 427. Compounds were formulated in 100% DMSO diluted 10-fold in distilled
water. Mice were treated on four consecutive days (d3 to d6 post-infection) with the Origanum onites oil,
as well as carvacrol and thymol, at 100 mg/kg by the i.p. route. One group served as untreated controls,
and two other groups were treated with the standard drugs pentamidine (5 mg/kg for 4 days) and
melarsoprol (2 mg/kg for 4 days), respectively. The levels of parasitemia of the mice were checked by
microscopic examination of tail blood on Day 7 and thereafter twice a week until Day 30 post infection.
Mice were considered cured when there was no parasitaemia relapse detected in the tail blood over the
30 day observation period. The day of relapse and surviving days were recorded.
5. Conclusions
Oregano oil is known to show a wide range of health benefits. The current study added another
potential use of oregano oil and its constituents in the area of infectious parasitic diseases. Although
the oil and its main constituents lack significant in vivo curative activity in mice, they may have
synergistic effects and exhibit enhanced bioactivity when combined with other constituents of the
oil, or with clinically used antiprotozoal drugs. Such small, stable, and cheap oil constituents, e.g.,
thymol, can serve as starting material to deliver new semi-synthetic antiparasitic agents with improved
activity profiles.
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